Biomarker Discovery in Patients With Advanced Biliary Tract Cancer

  • End date
    Mar 31, 2023
  • participants needed
  • sponsor
    CHA University
Updated on 13 August 2021


Biliary tract cancer is a rare gastrointestinal malignant neoplasm and includes intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gall bladder cancer. Curative surgical resection offers the only chance for cure. However, most patients with BTC are diagnosed at an unresectable stage. Therefore, the survival outcomes of patients with advanced biliary tract cancer remain dismal.

The combination of gemcitabine and cisplatin has become the current standard for advanced BTCs since the landmark ABC-02 trial in 2010. However, the median overall survival of Gem/Cis chemotherapy is less than 1 year. Recently, a triplet regimen of gemcitabine, cisplatin, and nab-paclitaxel showed promising results in a single-arm phase II multicenter study.

However, biliary tract cancer is a group of heterogenous diseases by site and genetic alteration, and this diversity may lead differences in response to systemic chemotherapy.

Transcriptome analysis through RNA-sequencing has rarely been performed in advanced biliary tract cancer, and even if it has performed, only small number of patients were included. Further research on multi-omics data is needed on the necessity and clinical significance in treatment of biliary tract cancer.


Using biopsy specimen (formalin fixed paraffin embedded tissue), in-house NGS and RNA-sequencing will be performed simultaneously. Through this, investigators will discover biomarkers based on multi-omics data that predict response to systemic chemotherapy (nab-paclitaxel plus gemcitabine-cisplatin). In addition, blood sampling will be performed in parallel to conduct research on cell-free DNA and circulating tumor cell analysis related to response and progression on chemotherapy; before administration of chemotherapy, 3 months after chemotherapy, 6 months after chemotherapy, the time of disease progression (if possible), before curative resection (if possible).

Condition Gall Bladder Cancer, Biliary Tract Cancer, Urothelial Tract Cancer, biliary cancer, Biliary neoplasm, gallbladder cancer, Adenocarcinoma, Gall Bladder Disorders, Malignant Adenoma, Gallbladder Disease, Cholangiocarcinoma, Malignant neoplasm of gallbladder, Gallbladder Carcinoma
Treatment nab-paclitaxel plus gemcitabine-cisplatin
Clinical Study IdentifierNCT04871321
SponsorCHA University
Last Modified on13 August 2021


Yes No Not Sure

Inclusion Criteria

Age 19 years old
Capable of understanding and complying with the protocol requirements and signed informed consent
The patients were confirmed as bilary tract cancer (gall bladder cancer, extrahepatic cholangiocarcinoma, intrahepatic cholangiocarcinoma) by histopathology or cytology
Patients with inoperable or metastatic or recurrent biliary tract cancer
Patients who underwent in-house next-generation sequencing
Patients planning to receive Gemcitabine, Cisplatin, nab-paclitaxel triplet chemotherapy
At least one measurable objective lesion was identified based on the RECIST 1.1 criteria
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
The expected survival a 3 months

Exclusion Criteria

The subject has uncontrolled, significant intercurrent or recent illness including infection for organ failure
Prior palliative chemotherapy for biliary tract cancer
Dementia, altered mental state, or any mental illness that prevents understanding or informed consent
Other conditions that researchers not think to be suitable for enrollment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note